Save time and get answers to complex questions with AI chat
When will there be a generic loreev available?What condition primarily benefits from sapropterin therapy?Patent tenofovir alafenamide gilead?What is the difference between apixaban and apixaban accord?Generic brand for latisse?
See the DrugPatentWatch profile for azacitidine
Effects of Azacitidine on GVHD Immune Cell Activity Azacitidine, a hypomethylating agent, has been shown to modulate immune cell activity and potentially mitigate graft-versus-host disease (GVHD) in clinical settings. GVHD is a major complication of allogenic hematopoietic stem cell transplantation (AHSCT), where donor immune cells attack the recipient's tissues. Understanding the effects of azacitidine on GVHD immune cell activity can help inform treatment strategies to prevent or manage this condition. Suppressing Immune Cell Activity Azacitidine has been found to suppress the activity of immune cells involved in GVHD, including T cells and natural killer (NK) cells. By inhibiting the proliferation and activation of these cells, azacitidine can help reduce the severity of GVHD [1]. Mechanisms of Action Studies have proposed several mechanisms by which azacitidine may affect GVHD immune cell activity. For example, azacitidine can: 1. Inhibit DNA methyltransferases, leading to the suppression of immune cells' capacity to produce pro-inflammatory cytokines [2]. 2. Induce apoptosis (programmed cell death) in activated immune cells, reducing their numbers and activity [3]. 3. Modulate the expression of genes involved in immune cell function, leading to a shift towards a more tolerogenic immune response [4]. Comparison with Other Treatments While azacitidine shows promise in modulating GVHD immune cell activity, its effects may differ from those of other treatments. Compared to cyclosporine, another immunosuppressive agent, azacitidine has been shown to have a similar efficacy but with reduced toxicity [5]. Clinical Relevance The potential of azacitidine to mitigate GVHD has significant clinical implications. Patients undergoing AHSCT may benefit from azacitidine treatment to reduce the risk of GVHD. Additionally, azacitidine may be used to manage GVHD in patients who have developed this complication despite initial immunosuppressive therapy. Patent Expiration Azacitidine's patent was initially set to expire in patent expiration date, source: DrugPatentWatch.com. However, this may have expired or been extended; please check for updates on current patent status. Sources [1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411519/ [2] https://www.ncbi.nlm.nih.gov/pubmed/24453319 [3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421414/ [4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4351316/ [5] https://www.ncbi.nlm.nih.gov/pubmed/25517311 Sources Cited 1. PubMed (PMC4411519, PMC4421414, PMC4351316, PMC4411519, PMID: 24453319) 2. DrugPatentWatch.com (US-6287972-B1)
Other Questions About Azacitidine :